Literature DB >> 9690755

Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration.

M M Morales Suárez-Varela1, M A Pérez-Benajas, V J Girbes Pelechano, A Llopis-González.   

Abstract

BACKGROUND: A study is made of the pharmaco-epidemiology of antacid (ATC class A02A) and antiulcer (A02B) drug prescriptions during the year 1992.
METHODS: Prescription data were extracted from 1941 case histories of patients over 15 years old from four health care centers in the Valencian Community (Spain). Dosage and treatment duration were evaluated, along with the way in which morbidity, self-evaluated health, the demographic pattern and life-style characteristics influence drug prescription.
RESULTS: The proportion of drug prescriptions increased with age in both sexes (p < 0.01). Drug use depended mainly on chronic diseases. In prescribing antacids, the most influential diagnosis was gastritis (ICD 534, OR: 157), followed by duodenal ulcer (ICD 532, OR: 152) and gastric ulcer (ICD 531, OR: 122), other gastrointestinal disorders (ICD 66, OR: 54) and undefined diagnoses (OR: 15). In the prescription of antiulcer drugs, the most influential diagnoses were gastric and duodenal ulcer (OR: 380 and 342, respectively), and a significant relation was observed with the diagnosis of osteomuscular diseases (OR: 6). Lifestyle and demographic pattern were of marginal importance. The estimated duration of treatment was 85 days. No significant differences were observed in either treatment duration or administered doses of almagate, ranitidine and omeprazole with respect to sex, age or diagnosis.
CONCLUSIONS: Prolonged treatment is common for acid suppression. The widespread use of peptic ulcer drugs is mostly due to excessive prescription for non-ulcer dyspepsia. At the same time, many patients consume these drugs on a long-term basis in the absence of a clear diagnosis. This observation supports the need for appropriate diagnostic and prescription protocols to secure increased economical savings and management results.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690755     DOI: 10.1023/a:1007493003891

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  31 in total

1.  Improving antiulcer agent prescribing in a health maintenance organization.

Authors:  D W Raisch; J L Bootman; L N Larson; W F McGhan
Journal:  Am J Hosp Pharm       Date:  1990-08

2.  Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial.

Authors:  D Y Graham; N M Agrawal; S H Roth
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

3.  Effect of cimetidine on surgery for duodenal ulcer.

Authors:  K D Bardhan; R F Hinchliffe
Journal:  Lancet       Date:  1981-07-04       Impact factor: 79.321

4.  Effect of cimetidine on surgery for duodenal ulcer.

Authors:  J H Wyllie; C G Clark; J Alexander-Williams; P R Bell; T L Kennedy; R M Kirk; C MacKay
Journal:  Lancet       Date:  1981-06-13       Impact factor: 79.321

5.  Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs.

Authors:  G Traversa; A M Walker; F M Ippolito; B Caffari; L Capurso; A Dezi; M Koch; M Maggini; S S Alegiani; R Raschetti
Journal:  Epidemiology       Date:  1995-01       Impact factor: 4.822

6.  Long term acid suppressing treatment in general practice.

Authors:  S D Ryder; S O'Reilly; R J Miller; J Ross; M R Jacyna; A J Levi
Journal:  BMJ       Date:  1994-03-26

7.  Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection.

Authors:  W de Boer; W Driessen; A Jansz; G Tytgat
Journal:  Lancet       Date:  1995-04-01       Impact factor: 79.321

8.  Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin.

Authors:  R Gotthard; G Bodemar; U Brodin; K A Jönsson
Journal:  Scand J Gastroenterol       Date:  1988-01       Impact factor: 2.423

9.  [Ulcer surgery and anti-ulcer agents. Changes in surgical activities and sale of anti-ulcer agents in Nord-Trøndelag 1975-89].

Authors:  R Haaverstad; O O Moen; K S Kannelønning; P D Line; A Wibe; T Bjerkeset
Journal:  Tidsskr Nor Laegeforen       Date:  1994-03-20

10.  Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial.

Authors:  S W Hosking; T K Ling; S C Chung; M Y Yung; A F Cheng; J J Sung; A K Li
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

View more
  1 in total

1.  Prevalence of anti-ulcer drug use in a Chinese cohort.

Authors:  Tzeng-Ji Chen; Li-Fang Chou; Shinn-Jang Hwang
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.